Genmab — Oktober 2016
-
men hvis de....
-
@bikube. Verden forandrer sig enormt hurtigt. Indtil for 3 måneder siden anbefalede stort set alle analytikere BMY pga Opdivos fantastiske evner. Et mislykket første linie studie i lungekræft, og de er bare fuldstændig yt
-
Roches Tecentriq er repræsenteret i 92 trials https://clinicaltrials.gov/ct2/results?term=Tecentriq&pg=5
-
og nævner et nyt studie, men det har nok været nævnt herinde https://clinicaltrials.gov/ct2/show/NCT02927925?term=daratumumab&rank=22
-
Tak JKY. Vi snakkede om det nye studie forleden. Ingen kendte noget til det på forhånd.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
